MedTrace Logo

Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility

NCT07164924 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2025-09-10

No results posted yet for this study

Summary

CONTEXT A desire for pregnancy is common in young patients with multiple sclerosis (MS). The impact of MS on women fertility is debated, and the impact of disease-modifying therapies (DMTs) on fertility is not well known. Antimüllerian hormone (AMH) is a representative biomarker of ovarian reserve that can be used to explore this issue.

OBJECTIVES To examine the impact of MS activity and related DMTs on ovarian reserve measured by serum AMH level.

METHODOLOGY Retrospective multicentre study based on clinical and blood samples from patients included in the OFSEP cohort. A serum sample from more than 800 MS and 96 NMOSD women aged 18-35 will be available for AMH dosing. The results obtained will be interpreted taking into account the age, the inflammatory activity of the disease, the disability (EDSS) and the previous and current DMTs used.

STATISTICAL ANALYSIS Spearman correlation coefficient will be calculated in univariate analysis between serum AMH level and number of relapses that occurred during the 2 years before blood sample collection. For multivariable analysis, multiple mixed linear regression will be performed with AMH level as dependant outcome and number of relapses, age, DMTs (highly active, moderately active or no treatment), disease duration and disability (measured using EDSS) as independent variables. The center will be considered as random-effect. For AMH level categorized as normal or not, mixed logistic regression will be performed with aforementioned covariates. These analyses will be completed by a mediation analysis between AMH level, number of relapses and DMTs with age, EDSS and disease duration as adjustments covariates.

EXPECTED RESULTS :

Evaluation of the potential relationship between AMH levels and MS or NMOSD activity at the first years of the illness.

Evaluation of the potential impact of MS and NMOSD treatments on ovarian reserve.

Optimization of the indications of fertility preservation for MS and NMOSD female patients.

Conditions

Interventions

BIOLOGICAL

blood sample to analyse AMH level on the serum

Evaluation of MS/NMOSD inflammatory activity on the serum AMH level (ng/ml)

Sponsors & Collaborators

  • Observatoire Français de la sclérose en plaques (OFSEP)

    collaborator UNKNOWN

  • Roche Diagnostic Ltd.

    collaborator INDUSTRY

  • ARSEP foundation

    collaborator UNKNOWN

  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • Pierre Clavelou · CHU de Clermont-Ferrand

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2024-12-08
Completion
2024-12-08

Countries

  • France
  • Martinique

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07164924 on ClinicalTrials.gov